Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Refractory Multiple Myeloma.

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

ONC-206 is under clinical development by Chimerix and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase II for Non-Small Cell Lung Cancer.

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19).